JP2018521027A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018521027A5 JP2018521027A5 JP2017563995A JP2017563995A JP2018521027A5 JP 2018521027 A5 JP2018521027 A5 JP 2018521027A5 JP 2017563995 A JP2017563995 A JP 2017563995A JP 2017563995 A JP2017563995 A JP 2017563995A JP 2018521027 A5 JP2018521027 A5 JP 2018521027A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- organ
- solution
- compound
- living tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 63
- 239000000243 solution Substances 0.000 claims description 41
- 239000012266 salt solution Substances 0.000 claims description 35
- 210000001519 tissue Anatomy 0.000 claims description 26
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 24
- 210000000056 organ Anatomy 0.000 claims description 21
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 18
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine group Chemical group [C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C=NC=2C(N)=NC=NC12 OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 18
- 210000002216 heart Anatomy 0.000 claims description 15
- 102000004877 Insulin Human genes 0.000 claims description 12
- 108090001061 Insulin Proteins 0.000 claims description 12
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims description 12
- 229940125396 insulin Drugs 0.000 claims description 12
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 12
- 229910001414 potassium ion Inorganic materials 0.000 claims description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 11
- 235000000346 sugar Nutrition 0.000 claims description 11
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 claims description 10
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 9
- 229960005305 adenosine Drugs 0.000 claims description 9
- 235000010323 ascorbic acid Nutrition 0.000 claims description 9
- 229960005070 ascorbic acid Drugs 0.000 claims description 9
- 239000011668 ascorbic acid Substances 0.000 claims description 9
- 239000000162 organ preservation solution Substances 0.000 claims description 8
- 238000001356 surgical procedure Methods 0.000 claims description 7
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 6
- 229910019142 PO4 Inorganic materials 0.000 claims description 6
- 229960004203 carnitine Drugs 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 6
- 239000010452 phosphate Substances 0.000 claims description 6
- 238000002054 transplantation Methods 0.000 claims description 6
- 239000004475 Arginine Substances 0.000 claims description 5
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 5
- 239000008121 dextrose Substances 0.000 claims description 5
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 5
- 210000004072 lung Anatomy 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 4
- 208000010496 Heart Arrest Diseases 0.000 claims description 3
- 230000002107 myocardial effect Effects 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 2
- 230000003293 cardioprotective effect Effects 0.000 claims description 2
- 210000001508 eye Anatomy 0.000 claims description 2
- 210000000936 intestine Anatomy 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 210000000952 spleen Anatomy 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 210000003932 urinary bladder Anatomy 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 239000001301 oxygen Substances 0.000 claims 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 241000255925 Diptera Species 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229910021529 ammonia Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 238000000034 method Methods 0.000 description 32
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 22
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 20
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 16
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 12
- 239000001103 potassium chloride Substances 0.000 description 11
- 235000011164 potassium chloride Nutrition 0.000 description 11
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 10
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 10
- 229910001629 magnesium chloride Inorganic materials 0.000 description 10
- 235000011147 magnesium chloride Nutrition 0.000 description 10
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 10
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 9
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 9
- 229960002173 citrulline Drugs 0.000 description 9
- 239000001630 malic acid Substances 0.000 description 9
- 235000011090 malic acid Nutrition 0.000 description 9
- 235000002639 sodium chloride Nutrition 0.000 description 9
- 108010024636 Glutathione Proteins 0.000 description 8
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 8
- 235000013477 citrulline Nutrition 0.000 description 8
- 229960003180 glutathione Drugs 0.000 description 8
- 229940037179 potassium ion Drugs 0.000 description 7
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 6
- 239000001110 calcium chloride Substances 0.000 description 6
- 229910001628 calcium chloride Inorganic materials 0.000 description 6
- 235000011148 calcium chloride Nutrition 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- 235000019341 magnesium sulphate Nutrition 0.000 description 6
- 229910000160 potassium phosphate Inorganic materials 0.000 description 6
- 235000011009 potassium phosphates Nutrition 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000001488 sodium phosphate Substances 0.000 description 6
- 229910000162 sodium phosphate Inorganic materials 0.000 description 6
- 235000011008 sodium phosphates Nutrition 0.000 description 6
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 6
- 108010087806 Carnosine Proteins 0.000 description 5
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 5
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 5
- 229960003624 creatine Drugs 0.000 description 5
- 239000006046 creatine Substances 0.000 description 5
- 229960005010 orotic acid Drugs 0.000 description 5
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 235000009697 arginine Nutrition 0.000 description 4
- 229940044199 carnosine Drugs 0.000 description 4
- 229940120124 dichloroacetate Drugs 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- MEJYXFHCRXAUIL-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;hydrate Chemical compound O.NC(=N)N(C)CC(O)=O MEJYXFHCRXAUIL-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229960004826 creatine monohydrate Drugs 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562173184P | 2015-06-09 | 2015-06-09 | |
| US62/173,184 | 2015-06-09 | ||
| PCT/US2016/036738 WO2016201126A1 (en) | 2015-06-09 | 2016-06-09 | Compositions and methods for tissue preservation at ambient or subnormothermic temperatures |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018521027A JP2018521027A (ja) | 2018-08-02 |
| JP2018521027A5 true JP2018521027A5 (cg-RX-API-DMAC7.html) | 2019-07-11 |
Family
ID=57504230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017563995A Pending JP2018521027A (ja) | 2015-06-09 | 2016-06-09 | 周囲温度または亜正常温度での組織保存のための組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20190082678A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3310161A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2018521027A (cg-RX-API-DMAC7.html) |
| CN (1) | CN108366552A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016274769A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112017026671A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2988974A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1251947A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016201126A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107509722B (zh) * | 2017-08-30 | 2020-11-10 | 迈克生物股份有限公司 | 样本保存液 |
| WO2020122928A1 (en) * | 2018-12-14 | 2020-06-18 | National Taiwan University | A stable cardioplegic solution for cardiac surgery |
| TWI781262B (zh) * | 2018-12-14 | 2022-10-21 | 國立臺灣大學 | 用於心臟手術之穩定心臟麻痺液 |
| CN109486747A (zh) * | 2018-12-24 | 2019-03-19 | 成都清科生物科技有限公司 | 一种间充质干细胞复苏保护液、制备方法和复苏方法 |
| EP3920846A4 (en) * | 2019-02-06 | 2022-11-09 | The Board and Trustees of the Leland Stanford Junior University | BIOLOGICALLY MODIFIED VASCULAR GRAPES FOR IMPROVED OUTCOMES IN BYPASS SURGERY |
| WO2020168191A1 (en) * | 2019-02-14 | 2020-08-20 | North Grove Investments, Inc. | Compositions for maintaining the viability of living and static biological material, methods of making and the uses thereof |
| WO2021183653A1 (en) * | 2020-03-10 | 2021-09-16 | University Of Florida Research Foundation, Incorporated | Compositions for extending viable preservation and shelf-life of organs and tissues |
| CN114052008A (zh) * | 2021-11-23 | 2022-02-18 | 中山大学附属第三医院(中山大学肝脏病医院) | 一种保存液及其应用 |
| EP4484546A4 (en) * | 2022-02-24 | 2025-11-12 | Blue Ind Inc | BIOLOGICAL SAMPLE PRESERVATIVE, BIOLOGICAL SAMPLE PRESERVATIVE PRODUCTION PROCESS, BIOLOGICAL SAMPLE PRESERVATION PROCESS, AND BIOLOGICAL SAMPLE PRESERVATION KIT |
| WO2023201038A1 (en) * | 2022-04-15 | 2023-10-19 | Marizyme, Inc. | Powder formulations and use thereof in medical and/or surgical procedures |
| KR102463256B1 (ko) * | 2022-05-02 | 2022-11-07 | 주식회사 프롬바이오 | 카페인 등을 이용한 지방조직 저온 또는 동결 보관용 조성물 및 이를 이용한 지방 조직의 보관 방법 |
| WO2023224887A1 (en) * | 2022-05-16 | 2023-11-23 | Marizyme, Inc. | Use of cytoprotectant formulations in cell or tissue transport and/or storage |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5405742A (en) * | 1993-07-16 | 1995-04-11 | Cyromedical Sciences, Inc. | Solutions for tissue preservation and bloodless surgery and methods using same |
| DE19706111C2 (de) * | 1997-02-17 | 1999-02-18 | Fresenius Medical Care De Gmbh | Lösung zur Aufbewahrung von Organen |
| US7611830B2 (en) * | 2000-04-10 | 2009-11-03 | The United States Of America As Represented By The Department Of Veteran's Affairs | Device to lavage a blood vessel |
| EP1809101B1 (en) * | 2004-11-12 | 2016-11-02 | Organoflush B.V. | Composition for cold preservation and perfusion of organs |
| AU2015201137B2 (en) * | 2007-02-17 | 2016-07-14 | President And Fellows Of Harvard College | Compositions and method for tissue preservation |
| EP2543249B1 (en) * | 2007-02-17 | 2018-05-23 | President and Fellows of Harvard College | Compositions and method for tissue preservation |
| WO2014106091A1 (en) * | 2012-12-31 | 2014-07-03 | Somahlution, Llc | Solution for preserving vascular conduits |
-
2016
- 2016-06-09 HK HK18111279.9A patent/HK1251947A1/zh unknown
- 2016-06-09 JP JP2017563995A patent/JP2018521027A/ja active Pending
- 2016-06-09 CA CA2988974A patent/CA2988974A1/en not_active Abandoned
- 2016-06-09 AU AU2016274769A patent/AU2016274769A1/en not_active Abandoned
- 2016-06-09 WO PCT/US2016/036738 patent/WO2016201126A1/en not_active Ceased
- 2016-06-09 BR BR112017026671A patent/BR112017026671A2/pt not_active Application Discontinuation
- 2016-06-09 EP EP16808306.1A patent/EP3310161A4/en not_active Withdrawn
- 2016-06-09 US US15/735,089 patent/US20190082678A1/en not_active Abandoned
- 2016-06-09 CN CN201680046574.XA patent/CN108366552A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105123670B (zh) | 用于进行组织保存的组合物以及方法 | |
| Toda et al. | Alteration of nitric oxide-mediated blood flow regulation in diabetes mellitus | |
| CA2988974A1 (en) | Compositions and methods for tissue preservation at ambient or subnormothermic temperatures | |
| Veres et al. | Custodiol-N, the novel cardioplegic solution reduces ischemia/reperfusion injury after cardiopulmonary bypass | |
| IL101637A0 (en) | Aqueous solutions for perfusion | |
| CA2809514A1 (en) | Perfusion composition | |
| ZA201504103B (en) | Organ and tissue preservation formulations with increased stability and shelf life | |
| EP1362511B1 (de) | Protektive Lösung zur Verhinderung von Ischämieschäden | |
| JP2018516955A5 (cg-RX-API-DMAC7.html) | ||
| JPWO2019017491A5 (cg-RX-API-DMAC7.html) | ||
| CA2950385A1 (en) | Gold (i)-phosphine compounds as anti-bacterial agents | |
| CN109789087A (zh) | 等渗晶体水溶液 | |
| JP2024098028A (ja) | 細胞および/または組織の輸送用組成物および/または凍結保存用組成物 | |
| EP1901605B1 (de) | Lagermedium für zellen | |
| JP2016537333A5 (cg-RX-API-DMAC7.html) | ||
| Chen et al. | Effective application of ET-Kyoto solution for clinical lung transplantation | |
| KR20150101498A (ko) | 아스타잔틴 또는 커큐민을 포함하는 돼지 정자 동결보존용 조성물 | |
| US20080286745A1 (en) | Methods and Solutions for Tissue Preservation | |
| KR20160108280A (ko) | 아스타잔틴 또는 커큐민을 포함하는 돼지 정자 동결보존용 조성물 | |
| RU2777097C1 (ru) | Способ рекондиционирования донорского сердца | |
| Pisarenko et al. | Effect of exogenous amino acids on the contractility and nitrogenous metabolism of anoxic heart | |
| ES2536785T3 (es) | Procedimiento para enriquecer cultivos con yodo, y cultivos obtenidos de este modo | |
| CN104706573A (zh) | 三磷酸腺苷二钠注射液 | |
| White et al. | Impact of initial reperfusion temperature on the functional recovery of DCD hearts | |
| KR20130021958A (ko) | 인공 수액 |